KINETICOS DISRUPTOR FUND

Kineticos Disruptor Fund will invest in disruptive modalities including cell therapy approaches such as CAR Ts, TCRs, TILs, gene therapy, gene editing, RNAi, immuno-oncology, and related precision medicine technologies. The Fund will focus on large, unmet medical needs in oncology, neurosciences, and rare diseases. In oncology, new approaches to solid tumors and “off the shelf” allogeneic cell therapies are immediate priorities.